The most viewed presentations, reports, and documents from Revolution Medicines.
Revolution Medicines RMC-6236 RAS Inhibitor 2023
investor_presentation
30 Pages
Revolution Medicines RMC-6236 Phase 1 KRAS Inhibitor 2023
conference
1 Pages